指南与共识泌尿与男性生殖病理

ISUP共识会议工作组4:睾丸前驱病变会前调查结果

International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey.
指南 / 共识 · Am J Surg Pathol · 2026-02-23

为筹备2024年ISUP泌尿生殖系统前驱病变共识会议,向ISUP成员发放匿名调查以评估睾丸前驱病变的诊断实践。调查显示,大多数病理学家认同GCNIS为GCT前驱病变的首选术语,并倾向使用OCT3/4作为主要免疫组化标记,但免疫组化确认前驱病变的必要性未达成共识。

要点

  • GCNIS是GCT前驱病变的首选术语,浸润性GCT中应报告其存在。
  • 多数病理学家使用OCT3/4作为主要免疫组化标记,通常不认为需要panel。
  • 免疫组化确认睾丸GCT前驱病变的必要性未达成共识。

核心结论

  • GCNIS是GCT前驱病变的首选术语,且其存在应在浸润性GCT病例中报告。

研究设计与样本

  • 在2024年ISUP共识会议前,向ISUP成员发放匿名调查,评估睾丸前驱病变的诊断实践。

主要发现

  • 调查显示,强烈同意GCNIS是GCT前驱病变的合适术语,且应在浸润性GCT中报告。
  • 同意「伴管内非精原细胞瘤的精原细胞瘤」是描述精原细胞瘤伴非浸润性非精原细胞成分的适当术语。
  • 多数病理学家偏好使用OCT3/4作为主要免疫组化标记,通常不认为需要panel。
  • 关于免疫组化确认睾丸GCT前驱病变的必要性,未达成共识。

关键数值与推荐

  • GCNIS是GCT前驱病变的首选术语,应在浸润性GCT中报告其存在。
  • 「伴管内非精原细胞瘤的精原细胞瘤」是精原细胞瘤伴非浸润性非精原细胞成分的适当术语。
  • 多数病理学家使用OCT3/4作为主要免疫组化标记,通常不认为需要panel。

临床怎么用

  • 病理诊断中应将GCNIS作为GCT前驱病变的首选术语,并在浸润性GCT中报告。
  • 对精原细胞瘤伴非浸润性非精原细胞成分,可使用「伴管内非精原细胞瘤的精原细胞瘤」术语。
  • 免疫组化可优先使用OCT3/4,通常不需panel。

局限性

  • 调查未就免疫组化确认睾丸GCT前驱病变的必要性达成共识。
  • 管内病变亚型分型的价值、性腺母细胞瘤的免疫组化方法、支持细胞结节与肿瘤的鉴别标准等问题仍未解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

According to the current WHO classification, noninvasive germ cell neoplasia of the testis comprises germ cell neoplasia in situ (GCNIS), specific forms of intratubular germ cell neoplasia, and gonadoblastoma. Because type II germ cell tumors (GCT, type II) arise from GCNIS, accurate detection of precursor lesions is diagnostically important. In preparation for the 2024 International Society of Urological Pathology (ISUP) Consensus Conference on genitourinary precursor lesions, which took place in Florence, Italy, an anonymous survey was distributed to ISUP members to assess current diagnostic practices regarding testicular precursor lesions. The literature and current WHO classification affirm the significance of precursor lesions in testicular tumours. Working Group 4-Precursor Lesions of the Testis-focused on their practical application by individual pathologists rather than establishing consensus from scientific data. There is strong agreement that GCNIS is the preferred and appropriate term for GCT precursor lesions and that its presence should be reported in cases of invasive GCT. Respondents also agree that "seminoma with intratubular nonseminoma" is the appropriate terminology for seminoma with an associated noninvasive nonseminomatous (embryonal carcinoma, yolk sac tumor, trophoblasts, or teratoma) component. Most pathologists prefer to use OCT3/4 as the primary immunohistochemical marker, and a panel was generally not considered necessary. No consensus is reached regarding the requirement for immunohistochemistry to confirm GCT precursor lesions in the testis. Three questions remain open: the value of subtyping intratubular lesions, the immunohistochemical approach to gonadoblastoma, and the criteria distinguishing Sertoli cell nodules from Sertoli cell tumors.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Bremmer F, Colecchia M, Collins K, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting Survey. Am J Surg Pathol. 2026. PMID: 41724745. doi:10.1097/PAS.0000000000002523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。